NR3C2 and bipolar disorder: The use of spironolactone add‐on treatment as a mineralocorticoid receptor antagonist to sodium valproate in the manic episode of bipolar disorder among a group of hospitalized patients in this clinical trial was associated with an improvement in the cognitive status of these patients compared to placebo.